Answers are grounded in this paper and cite their sources.
Case report identifies cyclical fixed drug eruption in a woman, suggesting hormonal influence on skin reactions.
Dear Editor, Autoimmune progesterone dermatitis (APD) is an uncommon condition characterized by a hypersensitive response to endogenous or exogenous progesterone. It cyclically affects women of reproductive age, typically during the luteal phase of the menstrual cycle.[1] The clinical manifestations are diverse, ranging from cyclical urticaria, fixed drug eruption (FDE)-like lesions, vesiculobullous lesions, erythema multiforme, maculopapular rashes, purpura or petechiae, stomatitis, angioedema, eczema, asthma, and in severe cases, anaphylactic reactions or Stevens–Johnson syndrome-like presentations.[2,3] Although rare, FDE-like presentation is a recognized variant posing a significant diagnostic challenge as it mimics a classical drug reaction.[3] We present a case of a 30-year-old multiparous woman who presented with a 7-month history of recurrent, monthly fluctuating, symptomatic skin lesions on her right upper arm and left forearm [Figure 1]. The lesions, characterized by erythematous to hyperpigmented patches, appeared 3–4 days before her menstrual period, accompanied by itching, burning, and occasional blistering. They resolved spontaneously within days after the onset of menses, leaving residual hyperpigmentation. There was no history of recent drug intake. Her history included a medical termination of pregnancy 8 years prior.Figure 1: A well-defined hyperpigmented patch (4 × 3 cm2) on the upper lateral aspect of the right arm with erythematous haloCutaneous examination revealed two well-defined hyperpigmented patches, measuring 4 × 3 cm2 on the right arm and 3 × 3 cm2 on the left forearm, with a faint erythematous halo on the larger lesion. Mucosal, hair, nail, and systemic examinations were unremarkable. A provisional diagnosis of APD presenting as FDE was considered. An intradermal test was performed using 0.1 mL of aqueous progesterone (100 mg/mL) injected into a previous lesion and on unaffected skin. A normal saline injection served as a control. Approximately 35 minutes later, both sites of progesterone injection showed erythema, edema, and induration [Figure 2a and 2b], which persisted for 24 hours. The control site was negative. The transient inflammatory response at the nonlesional site reflects systemic progesterone sensitization, a phenomenon well described in progesterone hypersensitivity, rather than the induction of a new fixed drug eruption lesion. Importantly, during follow-up, the patient did not develop recurrent cyclical lesions at the intradermal test sites, indicating that testing did not convert those locations into future FDE foci. A skin biopsy from the lesion showed basal cell vacuolization and dermal pigment incontinence, confirming the histopathological features of FDE [Figure 3]. The cyclical history, positive provocation test, and supportive histology confirmed the diagnosis of APD.Figure 2: (a) Positive intradermal progesterone sensitivity testing; transverse (width) diameter 2.5 cm with adjacent negative control. (b) Positive intradermal progesterone sensitivity testing; longitudinal (length) diameter 3 cm with adjacent negative controlFigure 3: Basal cell vacuolar degeneration (circle), pigment incontinence in dermis (arrow) (Hematoxylin and eosin, 100×)The patient was initiated on a combined oral contraceptive regimen containing 3.0 mg drospirenone and 0.03 mg ethinyl estradiol, prescribed for 21 consecutive days in a 28-day cycle. APD symptoms commonly emerge 3–10 days before menstruation and resolve shortly after.[1] It can occur at any age, even as early as menarche.[2] Diagnosis is based on clinical history, examination, and intradermal progesterone testing as defined by Warin et al.; however, no standardized protocol exists.[4] Immediate or delayed hypersensitivity reactions occur, but negative results may appear in asymptomatic women, limiting test reliability as a sole criterion.[1,2,5] The positive intradermal test responses at both lesional and non-lesional sites in our patient suggest systemic sensitization rather than a purely localized pathological process. At the same time, the persistence of eruptions at fixed sites despite ongoing systemic progesterone exposure supports the presence of altered immunologic memory confined to the original lesional skin. FDE-like patches in APD persist because of localized immunologic memory, whereas intradermal injection simply induces a temporary hypersensitivity reaction without establishing long-term T-cell residency in that location. Consistent with this explanation, our patient did not develop new recurring FDE-like patches at the test sites during follow-up. Regarding the ethical concern surrounding provocation testing, only the minimal required dose (0.1 mL) was used, and the expected reaction is transient, resolving within hours to a day. The test is widely used in APD diagnostics, is considered safe when performed carefully, and does not induce persistent lesions or long-term morbidity. Informed consent was obtained before testing. The pathogenesis of APD remains obscure. It may involve multiple mechanisms (T cell-mediated, IgE-mediated, or autoimmune).[1] Sensitization may occur through cross-reactivity between progesterone and antibodies formed against other antigens resulting from infections, food, or medications.[4] Progesterone can activate mast cells, causing anaphylaxis despite negative tests. The absence of recent drug exposure indicates that endogenous hormonal fluctuations can trigger the disease in susceptible individuals, with premenstrual lesion onset suggesting a T-cell-mediated (Type IV) hypersensitivity mechanism. Foer et al. classified APD as endogenous, exogenous, or mixed and also proposed renaming it ‘progesterone hypersensitivity reaction’ due to limited autoimmune evidence.[5] The patient had a pregnancy termination at 7–8 weeks, 8 years prior. APD may impair fertility and in vitro fertilization (IVF) outcomes, such as pregnancy loss.[1] Symptoms may vary in pregnancy, possibly due to desensitization.[2] Management focuses on suppressing the endogenous progesterone surge. Our patient was successfully treated with a combined oral contraceptive, which inhibits ovulation, and with antihistamines and topical steroids for symptomatic relief. The use of drospirenone-containing contraceptives is strategic due to their anti-mineralocorticoid and antiandrogenic properties and lower cross-reactivity risk. For refractory cases, other options include GnRH analogs, tamoxifen, or progesterone desensitization protocols (for those requiring high-dose progesterone), especially in women seeking fertility.[2] Bilateral salpingo-oophorectomy is reserved for severe, treatment-resistant APD.[1] FDE-like morphology can easily be misattributed to a conventional drug reaction, leading to unnecessary investigations and delayed diagnosis. The key learning point is that it is imperative to elicit a detailed history regarding the relationship of skin lesions to the menstrual cycle in any woman of reproductive age.[1] Clinicians should maintain a high index of suspicion for APD in women with recurrent or cyclical fixed-type eruptions, even in the absence of drug exposure. Recognizing this pattern can lead to a straightforward diagnostic test and a targeted, effective treatment, significantly improving the patient’s quality of life. Further research is needed to clarify the cellular and molecular immunopathology of fixed drug eruptions in APD.
No takes yet. Share an insight, caveat, or question.
Ram et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: